Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,946Revenue $M8.4Net Margin (%)-691.7Altman Z-Score-2.8
Enterprise Value $M2,682EPS $-1.5Operating Margin %-114.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score475Pre-tax Margin (%)-422.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-29.0Quick Ratio23.9Cash flow > EarningsY
Price/Sales1195-y EBITDA Growth Rate %-38.1Current Ratio23.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-20.1Higher Current Ratio y-yY
Dividend Yield %4.5PEG--ROE % (ttm)-444.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M117ROIC % (ttm)-6.7Gross Margin Increase y-yN

Gurus Latest Trades with THRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THRXJoel Greenblatt 2015-03-31 Buy 0.01%$10.68 - $20.2
($15.13)
$ 16.6510%New holding52,837
THRXFirst Eagle Investment 2015-03-31 Add$10.68 - $20.2
($15.13)
$ 16.6510%Add 5.48%1,680,910
THRXSeth Klarman 2014-09-30 Reduce-0.28%$17.53 - $30.4
($22.87)
$ 16.65-27%Reduce 2.84%19,815,983
THRXSeth Klarman 2014-06-30 Reduce-0.23%$21.154 - $30.1
($23.88)
$ 16.65-30%Reduce 1.50%20,395,056
THRXSeth Klarman 2014-03-31 Add0.42%$24.31 - $32.63
($29.32)
$ 16.65-43%Add 2.79%20,705,801
THRXSeth Klarman 2013-12-31 Add1.65%$27.19 - $32.81
($29.19)
$ 16.65-43%Add 8.83%20,144,301
THRXFirst Eagle Investment 2013-12-31 Add0.03%$27.19 - $32.81
($29.19)
$ 16.65-43%Add 23.40%1,509,404
THRXSeth Klarman 2013-09-30 Add2.3%$28.86 - $34.36
($31.06)
$ 16.65-46%Add 11.92%18,510,371
THRXSeth Klarman 2013-06-30 Add2.85%$18.15 - $33.74
($26.83)
$ 16.65-38%Add 22.02%16,538,977
THRXFirst Eagle Investment 2013-06-30 Add0.08%$18.15 - $33.74
($26.83)
$ 16.65-38%Add 139.14%1,109,620
THRXFirst Eagle Investment 2012-06-30 Add0.01%$14.11 - $19.04
($16.72)
$ 16.65-0%Add 24.23%509,710
THRXSeth Klarman 2012-03-31 Add0.22%$13.21 - $16.28
($13.91)
$ 16.6520%Add 2.30%14,553,800
THRXFirst Eagle Investment 2012-03-31 Add0.01%$13.21 - $16.28
($13.91)
$ 16.6520%Add 25.59%410,310
THRXJulian Robertson 2011-09-30 Sold Out -1.2512%$14.05 - $20.04
($16.74)
$ 16.65-1%Sold Out0
THRXSeth Klarman 2011-09-30 Add0.84%$14.05 - $20.04
($16.74)
$ 16.65-1%Add 9.76%14,225,961
THRXFirst Eagle Investment 2011-06-30 Reduce-0.02%$17.07 - $23.13
($20)
$ 16.65-17%Reduce 33.79%326,710
THRXDavid Swensen 2011-03-31 Sold Out -6.58%$16.91 - $20.77
($18.79)
$ 16.65-11%Sold Out0
THRXJulian Robertson 2011-03-31 Reduce-0.35%$16.91 - $20.77
($18.79)
$ 16.65-11%Reduce 20.94%211,686
THRXFirst Eagle Investment 2011-03-31 Add0.02%$16.91 - $20.77
($18.79)
$ 16.65-11%Add 51.02%493,410
THRXWilbur Ross 2011-03-31 Sold Out $16.91 - $20.77
($18.79)
$ 16.65-11%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


THRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2015-05-11Buy85,579$1369260-100view
GLAXOSMITHKLINE PLC10% Owner 2015-03-02Buy92,674$18.06-7.81view
GLAXOSMITHKLINE PLC10% Owner 2014-11-04Buy832,456$15.368.4view
LEE JUNNINGSr. VP, Technical Operations 2014-08-13Sell53,424$22.5-26view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-08-12Sell28,156$22.13-24.76view
GLAXOSMITHKLINE PLC10% Owner 2014-08-11Buy172,651$22.66-26.52view
GLAXOSMITHKLINE PLC10% Owner 2014-05-09Buy317,770$26.89-38.08view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-03-03Sell65,806$36.73-54.67view
Mammen MathaiSVP, Research & Early Clin Dev 2014-02-14Sell35,000$39.36-57.7view
GLAXOSMITHKLINE PLC10% Owner 2014-02-11Buy342,229$37.55-55.66view

Press Releases about THRX :

    Quarterly/Annual Reports about THRX:

    News about THRX:

    Articles On GuruFocus.com
    Insiders' New Buys : MAC, SPB, PDVW, HNSN, THRX, RSG, CVX May 18 2015 
    Seth Klarman's Trades During Q1 2015 Apr 20 2015 
    Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
    Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
    Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
    Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
    Top Four from Baupost’s Seth Klarman Jul 18 2013 

    More From Other Websites
    THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 20 2015
    Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208 for Treatment of... May 20 2015
    THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 18 2015
    Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of... May 18 2015
    THERAVANCE INC Financials May 15 2015
    5 Stocks Insiders Love Right Now May 13 2015
    10-Q for Theravance, Inc. May 10 2015
    THERAVANCE INC Files SEC form 10-Q, Quarterly Report May 08 2015
    General Releases May 07 2015
    Theravance to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference May 07 2015
    Theravance Inc Earnings Call scheduled for 5:00 pm ET today May 06 2015
    THERAVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
    Theravance Reports First Quarter 2015 Financial Results May 06 2015
    Q1 2015 Theravance Inc Earnings Release - After Market Close May 06 2015
    Theravance Biopharma Announces New Employment Inducement Awards May 04 2015
    U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug May 01 2015
    THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 30 2015
    Theravance Biopharma to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 30 2015
    FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US Apr 30 2015
    FDA Approves BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma in the US Apr 30 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK